Long Term, Low Dose Genistein decreases Stem Cell Populations and Sensitizes Inflammatory Breast Cancer Cell Lines to Radiation
Journal Title: Cancer Studies & Molecular Medicine – Open Journal - Year 2015, Vol 2, Issue 1
Abstract
Local recurrence in inflammatory breast cancer is common and is associated with poor prognosis. Recurrence is driven by a small population of radioresistant breast cancer cells that have stem-like properties. Previous studies have shown that high doses of the soy isoflavone genistein have a growth inhibitory effect on tumor cells, and may sensitize non-inflammatory breast cancer cells to radiation. The objective of this study was to determine the effect of genistein on the growth and radioresistance of inflammatory breast cancer cells. We show that short-term treatment of inflammatory cell lines IBC3 and SUM149 with genistein decreases cell proliferation and mammosphere forming ability only at micromolar doses, but had minimal effect on stem cell marker expression and radioresistance of these cells. However, long term treatment with a low dose (nM) of genistein, which may mimic dietary intake, decreased stem cell populations and mammosphere forming ability and increased radiation, induced cell death in these lines. We propose that dietary intake of genistein may be associated with improved local response to treatment in inflammatory breast cancer by decreasing growth of breast cancer stem cells.
Authors and Affiliations
Jennifer Sims-Mourtada
Keywords
Related Articles
- EP ID EP552107
- DOI 10.17140/CSMMOJ-2-107
- Views 110
- Downloads 0
Skin Hypopigmentation in a Patient with Papillary Carcinoma Thyroid Treated with Sorafenib
Sorafenib is an oral multikinase inhibitor approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma and thyroid cancer. The dermatological side effects of sorafenib include palmar-plantar ery...
Application of Radionuclides and Antibody-Drug Conjugates to Target Cancer
Radionuclide therapy and antibody-drug conjugates are used to locate and kill cancer cells by the utilisation of monoclonal antibodies. These bio-vectors are able to transport a cytotoxic drug payload and/or radiation in...
Role of Molecular Imaging in Oncology
Molecular Imaging (MI) is an emerging technology for the early detection of disease, staging of the disease, and for monitoring response to therapy. It also offers a non-invasive method to detect in vivo biological funct...
Boosting Response: The Impact of Immune Checkpoint Inhibitors on Radiation Treatment Schedules
The recent FDA approvals of immunomodulatory drugs such as Nivoluvamab (Opdivo), Pembrolizumab (Keytruda) and Ipilimumab (Yervoy) for treatment of Non-small cell lung cancer (NSCLC) and melanoma have renewed interest in...
Dysadherin: A Novel Oncogenic Molecular Biomarker in Oesophageal Cancer
Dysadherin or FXYD5 is a transmembrane glycoprotein, identified for the first time in 2002 by a team of Japanese researchers.1 Although, it is generally accepted that most of its action is derived from the increased maxi...